Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xencor, an antibody discovery and development company, has entered into an antibody optimization collaboration with CSL, a biopharmaceutical company, which will provide CSL with access to Xencor's XmAb technology platform to enhance the antibody-dependent cell-mediated cytotoxicity effector function of its therapeutic antibodies.
Subscribe to our email newsletter
During the research phase of the collaboration, Xencor will provide CSL with the opportunity to utilize the technology broadly across its antibody candidate pipeline. Xencor has granted CSL several commercial licenses to move product candidates into development and ultimately commercialization which incorporate Xencor’s XmAb technology.
In addition to an upfront payment, CSL will pay Xencor development milestone payments and product royalties for each product commercialized that incorporates the Xencor technology.
Bassil Dahiyat, CEO of Xencor, said: “We are excited to collaborate with our CSL colleagues and enable their antibody products through the use of our XmAb technology.”